Business
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla., June 04, 2025--Cadrenal Therapeutics will participate at this year's BIO International Convention 2025, taking place June 16-19, 2025 in Boston.
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/d76540793752cf3363a6a08373111320"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pzKaM3UDZKuVrydS8wvS8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d76540793752cf3363a6a08373111320","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8VUskHEB_FKuru3kXnEqRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d76540793752cf3363a6a08373111320","width":1200,"height":278}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., June 04, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston.","length":378,"tagName":"p"},{"type":"text","content":"Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company’s strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at [email protected].","length":396,"tagName":"p"},{"type":"text","content":"The BIO International Convention is the world’s largest and most comprehensive biotechnology event, convening over 20,000 industry leaders from across the global life sciences ecosystem.","length":186,"tagName":"p"},{"type":"text","content":"About Cadrenal Therapeutics, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood cl...